MedImmune has one of the largest, most robust pipelines in biopharmaceuticals – with a focus on five key areas and over 120 research projects and product candidates in our portfolio.
MedImmune currently comprises nearly 50% of AstraZeneca's pipeline, and we continue to combine our collective expertise to build a rich, diverse portfolio of small- and large-molecule compounds. This allows us to search for solutions to unmet medical needs, regardless of therapeutic modality.
Our approach to developing innovative drug candidates is to design and select candidate molecules for optimal biological properties, as well as development properties. This ensures we have the best molecules going forward.
Our pursuit of innovative drug candidates includes biosuperior products for clinically-validated targets, rather than developing biosimilars intended to copy an original molecule. Biosuperiors are designed to enhance patient value by improving upon an existing product's efficacy, safety profile, route of administration, dosing frequency, or other tangible benefit.
Download the latest version of the AstraZeneca/MedImmune development pipeline.